RATIONALE AND OBJECTIVES: COPD is associated with an increased risk of lung cancer. We examined whether inhaled corticosteroids (ICS) used concomitantly with long-acting beta(2)-agonists (LABA) were associated with reduction in lung cancer risk in COPD patients. METHODS: We conducted a retrospective cohort study of patients with a first-time diagnosis of COPD (index date) between 1989 and 2003 who were initially free of lung cancer, had quit smoking, were aged >or=50 years at time of diagnosis, and were regular users of ICS, ICS/LABA concomitantly, or short-acting bronchodilators (SABD). A nested case-control design was applied to overcome the time-varying nature of treatment. RESULTS: We identified 7079 COPD patients who were regular users of the therapies of interest, of whom 127 subsequently had lung cancer and were matched to 1470 controls of same gender and age. Lung cancer was diagnosed in 6.0% of concomitant ICS/LABA users compared with 7.3% of ICS and 10.9% of SABD users. In multivariate analyses, reductions in lung cancer risk were observed, with hazard ratio (HR) 0.50 (95% confidence interval, 0.27-0.90) in ICS/LABA users and 0.64 (0.42-0.98) in ICS users, compared with SABD users. In assessing 'dose-response' relationships, we found risk reductions: HR of 0.75 (0.33-1.75) and 0.39 (0.19-0.79) in ICS/LABA users with 1-2 and 3+ prescriptions/year, respectively, and 0.88 (0.51-1.52) and 0.51 (0.30-0.84) in ICS users with 1-2 and 3+ prescriptions/year, respectively. CONCLUSIONS: Regular use of ICS, with and without LABA, may reduce the risk of lung cancer among former smokers with diagnosed COPD.
RATIONALE AND OBJECTIVES:COPD is associated with an increased risk of lung cancer. We examined whether inhaled corticosteroids (ICS) used concomitantly with long-acting beta(2)-agonists (LABA) were associated with reduction in lung cancer risk in COPDpatients. METHODS: We conducted a retrospective cohort study of patients with a first-time diagnosis of COPD (index date) between 1989 and 2003 who were initially free of lung cancer, had quit smoking, were aged >or=50 years at time of diagnosis, and were regular users of ICS, ICS/LABA concomitantly, or short-acting bronchodilators (SABD). A nested case-control design was applied to overcome the time-varying nature of treatment. RESULTS: We identified 7079 COPDpatients who were regular users of the therapies of interest, of whom 127 subsequently had lung cancer and were matched to 1470 controls of same gender and age. Lung cancer was diagnosed in 6.0% of concomitant ICS/LABA users compared with 7.3% of ICS and 10.9% of SABD users. In multivariate analyses, reductions in lung cancer risk were observed, with hazard ratio (HR) 0.50 (95% confidence interval, 0.27-0.90) in ICS/LABA users and 0.64 (0.42-0.98) in ICS users, compared with SABD users. In assessing 'dose-response' relationships, we found risk reductions: HR of 0.75 (0.33-1.75) and 0.39 (0.19-0.79) in ICS/LABA users with 1-2 and 3+ prescriptions/year, respectively, and 0.88 (0.51-1.52) and 0.51 (0.30-0.84) in ICS users with 1-2 and 3+ prescriptions/year, respectively. CONCLUSIONS: Regular use of ICS, with and without LABA, may reduce the risk of lung cancer among former smokers with diagnosed COPD.
Authors: Rinat Zaynagetdinov; Taylor P Sherrill; Vasiliy V Polosukhin; Wei Han; Jamie A Ausborn; Allyson G McLoed; Frank B McMahon; Linda A Gleaves; Amber L Degryse; Georgios T Stathopoulos; Fiona E Yull; Timothy S Blackwell Journal: J Immunol Date: 2011-11-02 Impact factor: 5.422
Authors: Dena Zeraatkar; Juan P de Torres; Tyler Pitre; Michel Kiflen; Terence Ho; Luis M Seijo Journal: BMC Pulm Med Date: 2022-07-17 Impact factor: 3.320
Authors: Mariana Guergova-Kuras; István Kurucz; William Hempel; Nadège Tardieu; János Kádas; Carole Malderez-Bloes; Anne Jullien; Yann Kieffer; Marina Hincapie; András Guttman; Eszter Csánky; Balázs Dezso; Barry L Karger; László Takács Journal: Mol Cell Proteomics Date: 2011-09-26 Impact factor: 5.911
Authors: Stefan Prekovic; Karianne Schuurman; Isabel Mayayo-Peralta; Anna G Manjón; Mark Buijs; Selçuk Yavuz; Max D Wellenstein; Alejandro Barrera; Kim Monkhorst; Anne Huber; Ben Morris; Cor Lieftink; Theofilos Chalkiadakis; Ferhat Alkan; Joana Silva; Balázs Győrffy; Liesbeth Hoekman; Bram van den Broek; Hans Teunissen; Donna O Debets; Tesa Severson; Jos Jonkers; Timothy Reddy; Karin E de Visser; William Faller; Roderick Beijersbergen; Maarten Altelaar; Elzo de Wit; Rene Medema; Wilbert Zwart Journal: Nat Commun Date: 2021-07-16 Impact factor: 14.919